Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Rima Al-awar"'
Autor:
Safoura Zangiabadi, Tania H. Watts, Methvin Isaac, Achire N. Mbanwi, Jaclyn C. Law, Michael Prakesch, Maria I. Edilova, Rima Al-awar, Kenneth Ting, Ali A. Abdul-Sater, Mark D. Minden, Andrea Arruda, David Uehling
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Oncoimmunology
article-version (VoR) Version of Record
Oncoimmunology
article-version (VoR) Version of Record
TRAF1 is a pro-survival adaptor molecule in TNFR superfamily (TNFRSF) signaling. TRAF1 is overexpressed in many B cell cancers including refractory chronic lymphocytic leukemia (CLL). Little has been done to assess the role of TRAF1 in human cancer.
Autor:
Levon Halabelian, Nozomu Sakai, David McLeod, Anne-Claude Gingras, Rima Al-awar, Hiroshi Nara, Dalia Barsyte-Lovejoy, Masoud Vedadi, David Dilworth, Hideto Fukushi, Stéphane Richard, Carlos Zepeda, Cheryl H. Arrowsmith, María Sánchez-Osuna, Ahmed Aman, Carlo C. dela Seña, Kozo Hayashi, Suzanne Ackloo, Magdalena M. Szewczyk, Yoshinori Ishikawa, Peter Brown, Fengling Li, Eric Bonneil, Mike Tyers, Mohammad S. Eram, Masayuki Takizawa, Amber L. Couzens, Shawna Organ, Rachel Harding, Shinji Takagi, Tsukasa Sugo
Publikováno v:
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-1 (2020)
Nature Communications, Vol 11, Iss 1, Pp 1-1 (2020)
Protein arginine methyltransferases (PRMTs) regulate diverse biological processes and are increasingly being recognized for their potential as drug targets. Here we report the discovery of a potent, selective, and cell-active chemical probe for PRMT7
Publikováno v:
Cancer Research. 81:1222-1222
Lung cancer is the most lethal cancer globally, accounting for 1.8 million deaths in 2018. Presently, there is a need for novel targets for the development of improved therapeutics. Data mining through genetic screens suggested that Cell Division Cyc
Publikováno v:
Biomaterials. 123:39-47
We developed a novel taxane-binding peptide (TBP) modified, biodegradable polymeric micelle that overcomes limitations of drug loading and poor serum stability typically seen with particle delivery, leading to enhanced pharmacokinetics and tumor dist
Autor:
Troy Ketela, L. Song, H. He, Rima Al-awar, M. Shi, Mansi Aparnathi, Richard Marcellus, Ratheesh Subramaniam, Benjamin H. Lok, Safa Majeed
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:S24
Autor:
Hansen He, Lifang Song, Ratheesh Subramaniam, Mansi Aparnathi, Rima Al-awar, Safa Majeed, Benjamin H. Lok, Troy Ketela, Richard Marcellus, Mary Shi
Publikováno v:
Radiotherapy and Oncology. 150:S37
Autor:
Nathan F. Schachter, Sean E. Egan, David Uehling, Robert Rottapel, Eldad Zacksenhaus, Jason Moffat, Troy Ketela, Rima Al-awar, Ahmed Aman, Tao Deng, Philip E.D. Chung, Jeff C. Liu, Zhe Jiang, Babu Joseph
Publikováno v:
Cancer Research. 74:2119-2130
HER2+ breast cancer is currently treated with chemotherapy plus anti-HER2 inhibitors. Many patients do not respond or relapse with aggressive metastatic disease. Therefore, there is an urgent need for new therapeutics that can target HER2+ breast can
Autor:
Richard Marcellus, Osamu Muto, Donna L. Senger, Rima Al-awar, Constanza Rioseco, Ahmed Aman, David L. Kaplan, Michael D. Blough, Marco A. Marra, Lauren Podmore, Greg J. Cairncross, Xueqing Lun, Steven J.M. Jones, David Uehling, Natalie Grinshtein, Stephen M. Robbins, Yaoqing Shen, Jake Lever
Publikováno v:
Oncotarget
Glioblastoma (GBM) is the most lethal and aggressive adult brain tumor, requiring the development of efficacious therapeutics. Towards this goal, we screened five genetically distinct patient-derived brain-tumor initiating cell lines (BTIC) with a un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3be14bdf7d9517ee953d8fec1df6663
https://eprints.gla.ac.uk/242669/1/242669.pdf
https://eprints.gla.ac.uk/242669/1/242669.pdf
Autor:
Mansi K. Aparnathi, Rima Al-awar, Lifang Song, Ratheesh Subramaniam, Richard C. Marcellus, Benjamin H. Lok
Publikováno v:
Cancer Research. 79:3925-3925
Objective: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy. Post-platinum-based chemotherapy, rapid relapse of chemoresistant tumor is commonly seen. Unidentifiable causative mutations and from reversible nature of acqu
Autor:
Linda Liao, Nicola Lyttle, Richard Marcellus, Jane Bayani, Rima Al-awar, L Bathurst, Jms Bartlett, Melanie Spears, Cheryl Crozier
Publikováno v:
Cancer Research. 79:P5-04
Background: Approximately 70% of all breast cancers are estrogen receptor positive (ER+) at diagnosis and are dependent on estrogen signaling for tumour growth and proliferation. Some ER+ breast cancers can be effectively treated with adjuvant endocr